German biotech company Cure Vac announced Monday that it had taken a step forward in the development of its coronavirus vaccine . 
The TÃ¼bingen based company said it has started a Phase 3 clinical trial with an expected enrolment of more than 35,000 participants at sites in Europe and Latin America . 
The vaccine candidate uses m RNA technology , like the Pfizer/Bio NTech and Moderna shots . 
Following completion of the trial , subjects will continue to be monitored in a one year extension study , which will collect additional data to evaluate long term safety , persistence of antibodies and the duration of efficacy . 
